Abstract: The invention relates to antibodies against the Platelet Derived Growth Factor Receptor beta (PDGFR ?), and the use thereof in diagnostic and/or therapeutic applications. In particular, it provides a (VHH) antibody that specifically binds PDGFR ? with an apparent binding affinity of less than 10 nM, preferably less than 5 nM, and which does not activate PDGFR ?. Also provided are PDGFR ? antibodies and conjugates thereof, and their application in the targeted delivery of a diagnostic agent, a therapeutic agent or a combination thereof to a tissue in a subject, in particular to fibrotic tissue comprising activated myofibroblasts.
Type:
Application
Filed:
February 5, 2021
Publication date:
May 30, 2024
Applicant:
BIORION TECHNOLOGIES B.V.
Inventors:
Hermannus STEEN, Gustaaf Johan Marie VAN SCHARRENBURG
Abstract: The invention relates to the field of medicine. Among others, it relates to biologically active analogs of interferons (IFNs) which show less unwanted side-effects and to the therapeutic uses thereof. Provided is an IFN analog, wherein the moiety mediating binding to its natural receptor is at least functionally disrupted and wherein the analog comprises a signaling moiety capable of mediating intracellular IFN activity, said signaling moiety being provided at its N-terminus, optionally via a linker, with at least one targeting domain capable of binding to a cell surface receptor other than the IFN receptor.
Type:
Application
Filed:
December 30, 2010
Publication date:
March 14, 2013
Applicant:
BIORION TECHNOLOGIES B.V.
Inventors:
Klaas Poelstra, Jai Prakash, Eleonora Beljaars, Ruchi Bansal